cholangiocarcinoma gene therapy (University of Alabama)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namecholangiocarcinoma gene therapy (University of Alabama)
Drug Alias Namecytosine deaminase gene therapy (University of Alabama)
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionCytosine deaminase stimulants
TargetsCytosine deaminase
Therapy Area/IndicationsCholangiocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Alabama At Birmingham
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Alabama At Birmingham
Active IndicationsN/A
Inactive IndicationsCholangiocarcinoma

Other Information

ATC CodeN/A
Related LinksN/A